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Research Article
Relationship of Serum HbA1c and 
Fasting Serum Lipids with Central 
Macular Thickness in Patients with 
Type 2 Diabetes Mellitus
Introduction
Diabetes mellitus (DM) is a serious metabolic syndrome 
associated with hyperglycemia due to either insulin resistance or 
insufficiency. This chronic disease affects many organs and leading 
to severe complications one of which is diabetic retinopathy (DR) 
[1,2]. DR is the most common micro vascular complications of 
long-standing DM. Various  diabetes  risk scores composed of both 
laboratory and non-laboratory parameters have been developed. 
But plasma glycosylated hemoglobin known as Hemoglobin 
A1c (HbA1c) is as an index of average glycemic control over the 
previous 2–3 months are currently used both for monitoring and 
diagnosing for patients with diabetes mellitus [3,4]. Increased HbA1c 
concentration is the most important risk factor for developing DM 
complications including DR which is presented with retinal bleeding, 
vascular occlusion, ischemia, neovascularization, edema of retina 
or macula. Diabetic macular edema (DME) remains a major cause 
of visual impairment and blindness in diabetic patients. Increased 
HbA1c concentration, elevated serum lipids, uncontrolled high blood 
Ayse Gul Kocak Altintas*, Mehmet 
Citirik and Bayram Gulpamuk
SB Ankara Ulucanlar Eye Training and Research 
Hospital
Dates: Received: 08 June, 2016; Accepted: 29 
August, 2016; Published: 30 August, 2016
*Corresponding author: Ayse Gul Kocak Altintas, 
Medical Doctor, Associated Professor, Ulucanlar, 
Cad. No: 59 06230, Altindag, Ankara, Turkey, Tel: 
90-312-3126261; Fax: 90-312-3124827; E mail: 
www.peertechz.com
ISSN: 2455-1414
Keywords: Central macular thickness; Diabetes 
mellitus; HbA1c; Serum lipids 
pressure, presence of nephropathy and/or neuropathy are the most 
important risk factor for predicting DR complications [5-9].
Optical coherence  tomography  (OCT) is a noninvasive 
imaging modality that enabled to in vivo visualize of biological 
tissues in human eyes. By OCT examination multiple thin slices, 
laminar sheet structural images of morphologic changes, including 
vitreomacular traction, diffuse retinal thickening, intraretinal cystic 
changes, subretinal fluid can be easily detected. The central macular 
thickness (CMT) has been the most commonly used parameter to 
evaluate DME, in clinical follow up and research trials [10,11].
The purpose of the current study was to determine the correlation 
between diabetic macular edema, examined by OCT, and both HbA1c 
and fasting serum lipids. 
Materials and Methods
The presented study protocol and informed consent forms were 
reviewed and approved by the local medical Ethics Committee of 
Diskapi Training and Research Hospital. This study was designed in 
accordance with the Declaration of Helsinki. 
Abstract
Background: Diabetic retinopathy, the most common retinal vascular disease, is the leading 
cause of new-blindness in adults during the third through sixth decades of life.
Purpose: To determine the correlation between central macular thickness (CMT) and both 
HbA1c and fasting serum lipids level in early stage non proliferative diabetic retinopathy.
Results: The patients were divided into two groups as HbA1c >8.67% (Group I, n: 60) and HbA1c 
≤8.67% (Group II, n: 72). The mean CMT of better eyes was 273.28±34.61 µm. The mean CMT of 
worse eye was 304.40±64.31 µm. According to comparison between Group I (HbA1c >8.67%) and 
Group II (HbA1c ≤8.67%) the mean CMT’s were not different in two groups (P: 0.37). 
Main findings: HbA1c level (8.76%) were significantly higher than normal upper limits in patient 
even under diabetic medication. In further analyses the mean CMT’s was not different in worse eye 
in Group I and Group II and it was not significantly different in better eyes in these two group either.
Conclusion: Even we did not observed any correlation between level of HbA1c and the degree 
of CMT statistically in either worse or better eye, result of our study showed that patient had increased 
macular thickness even early stage of NPDR while having significantly higher HbA1c even under 
systemic medication.
Brief Summary: The purpose of the current study was to determine the correlation between 
diabetic macular edema and both HbA1c and fasting serum lipids in early stage non proliferative 
diabetic retinopathy. We did not observed any correlation between level of HbA1c and the degree of 
central macular thickness (CMT) statistically in either worse or better eye. Our results may indirectly 
evidence of insufficient metabolic treatment can cause macular edema prior to other retinal signs.
Potential implications: Systemic risk factor for follow-up of macular edema secondary to 
diabetes mellitus.
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A retrospective analysis was conducted on 264 eyes of 132 patients 
with type 2 DM who had admitted to retina clinic in Ulucanlar 
Eye Education and Research hospital for routine ophthalmologic 
examination for the first time. A complete ophthalmologic examination 
including visual acuity and intraocular pressure measurement, 
anterior segment examination, dilated fundus examinations were 
performed to all patients. The presence of DM in all patients had 
been confirmed by the corresponding internal medicine department. 
The status of retinopathy was assessed by fundus photography, 
fluorescein angiography and also by optical coherence tomography. 
Early Treatment of Diabetic Retinopathy Study criteria were used to 
define stages of diabetic retinopathy. According to fundus findings 
patient who diagnosed Non Proliferative Diabetic Retinopathy 
(NPDR) included in this study. Patient with proliferative DR, eyes had 
received any treatment such as laser photocoagulation or intravitreal 
injections were excluded. Patients having history of any other ocular 
disease including any other retinal disease, glaucoma, uveitis and 
history of trauma or ocular surgery as well as patients being under 
control of another ophthalmology clinic for DR were not included.
Data on duration of diabetes, presence of other co-morbidities 
including hypertension, nephropathy, neuropathy, which are 
known to be associated with metabolic syndromes and any other 
systemic diseases were also checked. Types of diabetic treatment and 
antihypertensive or lipid lowering medications were obtained from 
each patient. For statistical evaluation data on age, gender, fasting 
serum lipid, high-density lipoprotein cholesterol (HDL), low-density 
lipoprotein cholesterol (LDL), triglyceride (TG), plasma HbA1c and 
central macular thickness (CMT) were obtained from each patient.
A SD-OCT volume scan (20×20 with 49 horizontal sections, ART 
15) including en face images and macular mapping image obtained 
with HRA2 (Heidelberg Retina Angiograph-Optical Coherence 
Tomography, Heidelberg Engineering, Heidelberg, Germany) of the 
macula was performed for each study eye. Retinal thickness in the 
Early Treatment Diabetic Retinopathy Study (ETDRS) subfields was 
analyzed by the retinal thickness (RT) map analysis protocol and CMT 
was determined. High quality images were obtained by eliminating 
motion artifacts using eye tracker system. Retinal findings including 
presence or absence of any other retinal pathology such as age related 
macular disease, hereditary maculopathy, macular cystic changes 
or diffuse macular thickening were evaluated by same observer and 
CMT were measured and recorded for statistical evaluation.
Statistical analyses of data were performed using with the 
Statistical Package for the Social Sciences software (SPSS Inc., 
Chicago, IL, USA) version 15. The variables were evaluated by 
analytical statistical methods. Kolmogorov-Smirnov/Shapiro-Wilks 
test used to assess normality of variables. Descriptive statistics 
were expressed as median, minimum-maximum, for non-normally 
distributed variables. In order to evaluate the correlations between 
non-normally distributed variables, the correlation coefficients and 
their significance were calculated using the Spearman’s correlation 
test. Mann-Whitney U test was used for evaluation of correlation 
between non-normally distributed numerical variables of groups. A 
p value <0.05 was considered significant.
Results
In the current study, out of 132 patients 48 (36.4%) were male 
and 84 (63.6 %) were female. The number of female patient was 
significantly higher than male subjects (P: 0.004). The mean age of the 
patients was 59±8.9 years (range, 38-80 years). In the female group 
mean age was 59±7.8 years (range, 38-74 years) while in male patient 
it was 56.5±8.8 (range, 39-80 years). The mean age of female patient 
was significantly higher than male patient. (P: 0.04)
Hypertension was present in 57 (43.2 %) patients, while 
nephropathy, neuropathy or any other systemic diseases were not 
present in any of the patients. Hypertension was found as a most 
frequent co-morbidity factor in diabetic patients in this study. There 
was also no significant difference between genders in terms of co-
morbidities.
The mean HbA1c was 8.67% (range, 6%-14.6%) which was 
significantly higher than the normal upper limits of testing laboratory 
value (6%). According to Kolmogorov-Smirnov test, HbA1c had 
normal distribution (P: 0.61) thus, for further evaluation, the patients 
were divided into two groups as HbA1c >8.67% (Group I, n: 60) and 
HbA1c ≤8.67% (Group II, n: 72). 
No one had clinically significant macular edema (CSME) on 
fundoscopic evaluation. The mean CMT of all eyes was 297.12 ± 
101.38 µm; the median was 279.75 µm (range, 201-550 µm). The 
central macular thickness was not symmetric in most of the patients 
and results of Kolmogorov-Smirnov test showed that CMT was not 
normally distributed. For statistical evaluation, the eye with higher 
CMT of each patient was considered as a worse and the eye with 
lower CMT of the same patient was considered as a better eye. The 
mean CMT of better eyes was 273.28±34.61 µm and the median was 
269.01 µm (range, 201-449 µm). The mean CMT of worse eye was 
304.40±64.31 µm and the median was 284 µm (range, 219-550 µm) 
(Table 1). According to these findings the CMT’s were higher than 
our (SD-OCT) normal laboratory limits of (250 µm) even in the 
minimally affected retinas in eyes with NPDR. All of these parameters 
about CMTs and HbA1c were significantly higher than that of normal 
reference values. On correlation analyses with Spearman’s correlation 
test, there was not any significant correlation between the HbA1c level 
and CMT of all eyes (R: -0.12 P: 0.16). In subgroup analyses there was 
not any correlation between HbA1c level and with worse or better 
eyes either (R:-0.07 P: 0.40; R:-0.05 P: 0.53 respectively). According to 
comparison between Group I (HbA1c >8.67%) and Group II (HbA1c 
≤8.67%) the mean CMT’s were not different in two groups (P: 0.37). 
In further analyses the mean CMT’s was not different in worse eye in 
Group I and Group II and it was not significantly different in better 
eyes in these two group either (P: 0.24 and P: 0.15 respectively).
Table 1: Central macular thickness (CMT) values in better and worst eyes in 
subject with high (>8.6) and low HbA1c (≤8.6).
CMT (µm) Group I (HbA1c>8,6) (n=60)
Group II (HbA1c≤8,6) 
(n=72) P-value*
Mean CMT 285.7 (212.5-464.5) 291.45 (228-456) 0,372
CMT of better eye 270.43 (201-449) 275.65 (212-378) 0,156
CMT of worse eye 300.96(219-504) 307.26 (229-550) 0,247
*Mann-Whitney U Test.
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The mean HDL, LDL and TG levels were 49.46±7.8 mg/dl, 
111.83±11.0 mg/dl, and 182.31±18.2 mg/dl respectively. Although 
result of Kolmogorov-Smirnov normalization test, each fasting serum 
lipids including HDL, LDL and TG had not normal distribution 
(p:0,00, p:0,03, p:0,00, respectively), according to laboratory analyses 
of the each fasting serum lipids were in normal laboratory ranges 
(Table 2). Therefore any further subgroup analyses about serum 
lipids level and its correlation with CMT did not performed. 
Discussion
HbA1c  is as an index of average glycemic control which is 
currently used both for diagnosing and monitoring for patients 
with diabetes mellitus in most clinics. Increased HbA1c concentration 
which is a quantitative indicator that shows poor diabetic control, 
furthermore, it is the most important risk factor for predicting DM 
complications such as diabetic retinopathy or maculopathy [1,2]. 
According to different laboratory cut of point, maintaining an HbA1c 
level below 6% or 6.5% is critical to decrease the incidence of diabetic 
complications. DR is among the most common complications of 
diabetes which can result in edema of the central retina or macula. 
DME is one of the major causes of vision impairment and blindness 
in patients with diabetes [12-14].
The purpose of the present study was to determine the 
correlation between CMT and HbA1c level in early stage NPDR. 
Our results showed that HbA1c level (8.76%) were significantly 
higher than normal upper limits in patient even under systemic 
diabetic medication. Benarous et al. [2], reported that HbA1c was 7.3 
in patient without DR while it was 8.0 in eyes with DR, 8.1 in eyes 
presented with DME, and 8.3 in eyes with CSME. Similarly, Jew et 
al. [15], found that HbA1c level was significantly higher in the eyes 
with CSME (10.38%) compared to that in eyes without CSME (7.8%).
Unsal et al. [16], also found a correlation with diabetic retinopathy 
stage, macular involvement and the mean HbA1c levels which were 
8.2% in the NPDR group, 9.5% in the eyes with PDR, and 9.0% in 
DME group. Sasaki et al. [17], evaluated 74 patient with no DR 
and 7 patient with only minimal DR and found that HbA1c level 
(7.2%) was above the normal upper limits. Cetin et al. [5], reported 
that HbA1c level was higher in eyes with DME (8.6%) than in eyes 
without DME (7.9%). According to multivariate analysis in Jew et al. 
[15], study, they showed that HbA1c levels were one of the significant 
risk factor for developing CSME. Even we did not observed CSME 
based on fundoscopic evaluation in none of our patient and we did 
not included the patient with PDR, all of our subjects with bilateral 
NPDR had increased HbA1c level similar to the other reports.
Unsal et al. [16], observed that the mean CMT (371 µm) in eyes 
with DME was significantly higher than the eyes with PDR (256 µm) 
and NPDR (253 µm). In series by Benarous et al. [2], the mean CMTs 
were 236 µm in eyes with DR, 250 µm in eyes with DME, and 301 
µm in eyes with CSME while it was only 215 µm in eyes without 
DR evaluated with time-domain OCT (TD-OCT). Each of these 
studies demonstrated positive associations between diabetic stage 
and macular thickness. Moreover Sasaki et al. [17], reported that the 
mean CMT was 273 µm in eyes with no (74) or minimal DR (7) which 
measured by SD - OCT. Their result was higher than that of other 
series such as even in eyes with DME reported in Benarous et al. [2], 
series. This difference may due to measurement quality using with 
different type of OCT. SD-OCT has the greater resolution which has 
more sensitive in evaluation and measurement than TD-OCT. The 
CMT in presenting study was measured by SD-OCT similar to Sasaki 
et al. [17], series. The mean CMT was 297.12 µm which was higher 
than that of their series. The difference may related to diabetic stage 
in which each 264 eyes of 132 patients in our series had NPDR while 
only 7 eyes had minimal DR in Sasaki et al [17] series.
There are several conflicting reports in the literature regarding the 
effect of lipid profile on CMT and maculopathy. Cetin et al [5] did not 
observe any association with total cholesterol, TG or LDL levels and 
macular edema. Benarous et al. [2], showed that serum lipid levels 
were not correlated with both CMT and macular volume. Similarly, 
Sasaki et al [17] reported that with covariables adjustment each serum 
lipids; total cholesterol, HDL, and TG levels were not significantly 
associated with both CMT. In the presenting study while the mean 
fasting serum lipid levels were in the range of reference levels, the 
mean CMT were higher than the normal limits that may be indirect 
evidence of absence of any correlation between the macular thickness 
and the serum lipid profile. 
As far as we know even the correlation of HbA1c levels with DM 
complications have evaluated by several investigators there was not 
any study has focused on the correlation between HbA1c level and 
CMT in eyes with naive NPDR. To quantitatively evaluated the level 
of macular thickness both in better and worse eye and its correlation 
with HbA1c in eyes with naive DR, only the patients who were 
admitted to ophthalmology clinic for the first time were examine. 
In order to minimize the effect of confounding factors related to 
treatment either with laser or intravitreal injections and the severity 
of DR, we examined only the treatment-naive eyes with minimal 
NPDR. Even we did not observed any correlation between level of 
HbA1c and the degree of CMT statistically in either worse or better 
eye of patient with DR, result of our study showed that patient had 
increased macular thickness even early stage of NPDR while having 
significantly higher HbA1c even under systemic medication. Our 
results may indirectly evidence of insufficient metabolic treatment 
can cause macular edema prior to other retinal signs. The limitation 
of our retrospective study is evaluation of correlation between CMT 
and duration of diabetes. Further studies are necessary to evaluate 
how both maculas are asymmetrically affected by same systemic risk 
factors in same subject and fine cut-off point of HbA1c for increment 
of CMT.
Table 2: Patients fasting serum lipid level according to Kolmogorov-Smirnov’s 
normalization test, none of these parameters were in normal distribution. 
Patient’s serum glycosylated hemoglobin (HbA1c) level was in normal 
distribution tested by Kolmogorov-Smirnov’s test.
HDL (mg/dl) LDL (mg/dl) TG (mg/dl) HbA1C (%)
Mean (mg/dl) 49.46 111.83 182.31 8.67
Maximum (mg/dl) 87 294v 585 14.6
Minimum (mg/dl) 25 28 54 6
Reference Value 45-65 0-130 0-200 4-6
P Value 0.00 0.03 0.00 0.61
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